COVID-19 vaccine: Bangladesh's Beximco Pharma ties up with India's Serum Institute

Beximco Pharmaceuticals, one of the leading drugmakers of Bangladesh, announced it will invest with the Serum Institute of India (SII) to ensure Bangladesh receives COVID-19 vaccine on a priority basis, once approved by the regulator

Aug 29, 2020

Beximco Pharmaceuticals, one of the leading drugmakers of Bangladesh, announced it will invest with the Serum Institute of India (SII) to ensure Bangladesh receives COVID-19 vaccine on a priority basis, once approved by the regulator.

The announcement came more than a week after Indian Foreign Secretary Harsh Vardhan Shringla's visit to Dhaka and a day after the Bangladesh government announced approval of the stage three trial of a vaccine of Chinese company -- Sinovac Research and Development Co Ltd.

During Shringla's visit, Dhaka had sought to collaborate with Indian vaccine developers for trial in Bangladesh. The secretary did not speak of any collaboration for the trial, but said Bangladesh would be a priority country in terms of getting COVID-19 vaccines once developed and approved.

https://www.thedailystar.net/frontpage/news/beximco-pharma-ties-indian-firm-1952677

Post a Comment

SAM Vignettes

South Asia Monitor, a resource on, about and of relevance to India and South Asia, is proud to introduce WASHINGTON CALLING, a weekly video and documentary feature powered by Frank Islam, Washington-based entrepreneur, philanthropist and thought leader. It will feature interviews with Washington/US based journalists, lawmakers, diplomats and other professionals as well strategic analysts, journalists and others from India. It will also air occasional documentaries of interest to an India and South Asian audience globally.